Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced that it has received marketing approval from Bolivia’s Agencia Estatal de Medicamentos y Tecnologías en Salud (AGEMED) for its Insulin Aspart (cartridge bottle). Insulin Aspart, a rapid-acting insulin analogue, begins to take effect within 10-20 minutes of subcutaneous injection, with a maximum duration of action occurring 1-3 hours post-injection and an overall action duration of 3-5 hours. This medication is instrumental in effectively managing postprandial blood sugar levels.
According to the latest data from the International Diabetes Federation (IDF)’s IDF Diabetes Atlas (2021), in 2021, there were approximately 395,900 diabetes patients aged 20-79 in Bolivia, with an annual expenditure related to diabetes per patient amounting to USD 898.8. The incidence rate of diabetes among adults aged 20-79 in Bolivia was 5.7%. Novo Nordisk (NYSE: NVO), the originator of Novolog, supplies the drug in Bolivia and achieved global sales of DKK 15.46 billion (USD 2.27 billion) in 2022.- Flcube.com